Published online Apr 14, 2024. doi: 10.3748/wjg.v30.i14.2018
Peer-review started: October 31, 2023
First decision: December 15, 2023
Revised: January 11, 2024
Accepted: February 29, 2024
Article in press: February 29, 2024
Published online: April 14, 2024
Processing time: 164 Days and 10.5 Hours
Colorectal cancer (CRC) ranks among the most prevalent malignant tumors globally. Recent reports suggest that Fusobacterium nucleatum (F. nucleatum) contributes to the initiation, progression, and prognosis of CRC. Butyrate, a short-chain fatty acid derived from the bacterial fermentation of soluble dietary fiber, is known to inhibit various cancers. This study is designed to explore whether F. nucleatum influences the onset and progression of CRC by impacting the intestinal metabolite butyric acid.
To investigate the mechanism by which F. nucleatum affects CRC occurrence and development.
Alterations in the gut microbiota of BALB/c mice were observed following the oral administration of F. nucleatum. Additionally, DLD-1 and HCT116 cell lines were exposed to sodium butyrate (NaB) and F. nucleatum in vitro to examine the effects on proliferative proteins and mitochondrial function.
Our research indicates that the prevalence of F. nucleatum in fecal samples from CRC patients is significantly greater than in healthy counterparts, while the prevalence of butyrate-producing bacteria is notably lower. In mice colonized with F. nucleatum, the population of butyrate-producing bacteria decreased, resulting in altered levels of butyric acid, a key intestinal metabolite of butyrate. Exposure to NaB can impair mitochondrial morphology and diminish mitochondrial membrane potential in DLD-1 and HCT116 CRC cells. Consequently, this leads to modulated production of adenosine triphosphate and reactive oxygen species, thereby inhibiting cancer cell proliferation. Additionally, NaB triggers the adenosine monophosphate-activated protein kinase (AMPK) signaling pathway, blocks the cell cycle in HCT116 and DLD-1 cells, and curtails the proliferation of CRC cells. The combined presence of F. nucleatum and NaB attenuated the effects of the latter. By employing small interfering RNA to suppress AMPK, it was demonstrated that AMPK is essential for NaB’s inhibition of CRC cell proliferation.
F. nucleatum can promote cancer progression through its inhibitory effect on butyric acid, via the AMPK signaling pathway.
Core Tip: In this study, we unravel the mechanism of Fusobacterium nucleatum (F. nucleatum) in the progression of colorectal cancer (CRC), focusing on the interplay between intestinal flora and metabolism. Our results reveal that F. nucleatum suppresses the production of the short-chain fatty acid butyric acid. We discovered that sodium butyrate impairs mitochondrial function and impedes the cell cycle in CRC cells. Furthermore, the study highlights that both sodium butyrate and F. nucleatum orchestrate CRC cell proliferation via the adenosine monophosphate-activated protein kinase signaling pathway. These insights may enhance our understanding of CRC pathogenesis and aid in the development of more effective treatment strategies.